Introduction
============

Traditional Chinese medicine (TCM), especially Chinese herbal medicine (CHM) and acupuncture, is an ancient medical system used in China and other Asian countries for thousands of years \[[@B1],[@B2]\]. In contrast to the reductionist approach of Western medicine based on modern anatomy, physiology, pathology, pharmacology as well as cell and molecular biology, TCM uses a unique system and an individualised and holistic approach to describe health and disease, based on the philosophy of Yin-Yang balance and an emphasis on harmony of functions. These two medical systems differ greatly in many respects. In the past seven years, a number of international organisations were established in mainland China, Hong Kong and Macao, including the World Federation of Chinese Medicine Societies (WFCMS, September 2003), the Consortium for Globalisation of Chinese Medicine (CGCM, December 2003) and the International Society for Chinese Medicine (ISCM, 2004).

The Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era (GP-TCM) consortium was launched by the European Commission on the 1^st^May 2009. This is a three-year coordination action project funded under the EU Seventh Framework Programme (FP7) with a total budget of €995,100. The central hypothesis of the consortium is that, using functional genomics technology, which allows high-content observations of whole profiles of molecules at different levels, *eg*DNA, mRNA, protein and metabolites, and furthermore linking them to clinically relevant biological functions, we might be in a better position than ever before to interpret and validate the scientific value of TCM in a holistic and function-oriented manner \[[@B3]-[@B11]\].

Objectives
----------

Focusing on research of CHM and acupuncture, we especially emphasise studies of CHMs, their complex chemical ingredients and their holistic impact on the functional genomics of patients. The overall aim of the consortium is to inform the best practice and harmonise research on the safety and efficacy of TCM using a functional genomics approach through exchange of opinions, experience and expertise among scientists in EU member states, China and other parts of the world. Specifically, we aim to undertake the following objectives:

• Develop a European-Chinese network, collaborating on functional genomics research of TCM;

• Review current practice of TCM research, identify problems and propose solutions;

• Propose standard protocols of methodology;

• Propose priority areas for future research;

• Develop online resources to support and enhance pan-European studies of TCM research;

• Facilitate and foster a sustainable European collaboration by founding a European society dedicated to TCM research.

Structure
---------

As shown in Figure [1](#F1){ref-type="fig"} through ten working groups known as work packages (WPs), the consortium takes actions to review the techniques, identify problems and solutions in the quality control (WP1), extraction and analysis (WP2) of CHMs. While these fundamental issues are addressed, discussion forums emphasising the use of functional genomics methodology in research of the safety, efficacy and mechanisms of CHMs (WP3-WP7) and acupuncture (WP8) form the core of this coordination project. The project covers toxicology (WP3), *in vitro*and *in vivo*pharmacology (WP4-WP5), clinical studies (WP6), as well as international regulatory issues of CHM (WP7). WP9 is dedicated to organising the Final Conference of the consortium at the end of the project and WP10 is charged to manage consortium-wide matters, such as appointment and coordination of WP leadership, recruitment of additional experts, editing website and newsletters, drafting standard operating procedures, providing scientific and technological support and guidance, organising internal review and quality assurance, as well as liaising with the Commission and other stakeholders and external authorities.

![**Structure of the GP-TCM Consortium**. GP-TCM work package interaction and relationship: GP-TCM has ten interactive working groups, known as work packages (WP). WP1-WP7 specialises in quality control, component extraction and chemical analysis, toxicology, *in vitro*and *in vivo*pharmacology, clinical studies and regulatory issues in commercial R&D respectively. WP8 is specialised in acupuncture studies and WP9 is dedicated to organising the Final conference of the consortium, at which a new European society will be launched to succeed the mission of the consortium. WP10 is the managing, coordinating and leading body of the whole consortium, aiming at integrating the expertise and collating outputs of all WPs to achieve the overall objectives of the consortium.](1749-8546-5-42-1){#F1}

Membership
----------

As shown in Table [1](#T1){ref-type="table"} the consortium has 27 beneficiary (*ie*funded) partner organisations across ten EU member states (*ie*Austria, Belgium, Estonia, Germany, Ireland, Italy, the Netherlands, Portugal, Spain and the UK) and China, which is an International Cooperation Partner Country (ICPC) of the EU. The consortium has additional 60 non-beneficiary (*ie*unfunded) collaborating partner organisations as well as two independent experts from Australia, Austria, Belgium, China, Denmark, Finland, Germany, Italy, Luxembourg, the Netherlands, Norway, Thailand, the UK and the USA (Table [2](#T2){ref-type="table"}). Please refer to the project website at <http://www.gp-tcm.org/about/partners/> for an updated list of consortium partners. This forms a diverse, multicultural and multidisciplinary team of about 150 principal investigators, including leading scientists, clinicians, TCM practitioners, as well as experts in industrial development and regulatory issues. Non-beneficiary membership is mainly based on consortium invitation and requires outstanding expertise needed for the project. Interested parties are welcome to contact us via the GP-TCM website <http://www.gp-tcm.org/contact/>. GP-TCM currently covers half of the 27 EU member states and its members in China are largely in major eastern and southern cities. As an open-ended consortium, GP-TCM welcomes interested parties from all EU member states and China to join our network, sharing resources and forging collaborations. We will continue to develop and strengthen collaborations with friends in Africa, South America, Asia and non-EU European countries to exchange experience and lessons learnt in the research of traditional medicines.

###### 

GP-TCM beneficiary members

  GP-TCM beneficiary partners                           Country           Contact
  ----------------------------------------------------- ----------------- ---------------------------------
  King\'s College London                                UK                Dr. Qihe Xu
  University of Vienna                                  Austria           Prof. Verena M. Dirsch
  L\'Université Libre de Bruxelles                      Belgium           Prof. Pierre Duez
  Beijing University of Chinese Medicine                China             Prof Yanjiang Qiao
  China Capital Medical University                      China             Prof. Xiaomin Wang
  Institute of Medicinal Plant Development              China             Prof. Xinmin Liu
  Shanghai Institute of Acupuncture-Moxibustion         China             Prof. Huangan Wu
  Shanghai University of Traditional Chinese Medicine   China             Dr. Liu Chenghai
  University of Hong Kong                               China             Dr. Hani El-Nezami
  Asper Biotech Ltd                                     Estonia           Ms. Janne Üksti
  Federal Institute for Drugs and Medical Devices       Germany           Dr. Werner Knöss
  University of Düsseldorf                              Germany           Prof. Peter Proksch
  University of Munich                                  Germany           Prof. Angelika Vollmar
  University of Bonn                                    Germany           Prof. Gabriele König
  Trinity College Dublin                                Ireland           Dr. Helen Sheridan
  University of Milan                                   Italy             Prof. Enrica Bosisio
  University of Padova                                  Italy             Prof. Maria Carrara
  CMC Tasly Group BV                                    The Netherlands   Dr. You-Ping Zhu
  Leiden University                                     The Netherlands   Prof. Robert Verpoorte
  University of Minho                                   Portugal          Prof. Alberto Dias
  University of Alcala                                  Spain             Prof. F. Javier de Lucio Cazaña
  University Hospital Ramón y Cajal-FIBIO               Spain             Dr. M. Laura García Bermejo
  Acu-herb Consultant, Sheffield                        UK                Ms. Dan Jiang
  University of Wolverhampton                           UK                Prof. Kelvin Chan
  Royal Botanic Gardens, Kew                            UK                Prof. Monique Simmonds
  University of Southampton                             UK                Prof. George Lewith
  University of Cambridge                               UK                Dr. Tai-Ping Fan

###### 

GP-TCM non-beneficiary members

  GP-TCM Non-beneficiary partners                                                       Country           Contact
  ------------------------------------------------------------------------------------- ----------------- ----------------------------
  University of Western Sydney                                                          Australia         Prof. Alan Bensoussan
  University of Graz                                                                    Austria           Prof. Rudolf Bauer
  University of Mons                                                                    Belgium           Prof. Jean-Marie Colet
  Beijing East Linden Science and Technology Co. Ltd.                                   China             Prof. Yanhuai Liu
  China Academy of Chinese Medical Sciences                                             China             Prof. Aiping Lu
  China-Japan Friendship Hospital                                                       China             Prof. Ping Li
  Dalian Institute of Chemical Physics                                                  China             Prof. Xinmiao Liang
  Hong Kong Baptist University                                                          China             Prof. Zhongzhen Zhao
  Hong Kong Buddhist Hospital                                                           China             Prof. Vivian Wong
  Jinan University                                                                      China             Prof. Xinsheng Yao
  Peking University                                                                     China             Prof. Wenhan Lin
  PuraPharm                                                                             China             Mr. Abraham Chan
  Shanghai Innovation Research Centre of Traditional Medicine                           China             Prof. William Weiguo Jia
  Shanghai Jiaotong University                                                          China             Prof. Liping Zhao
  Shanghai Institute of Materia Medica, Chinese Academy of Sciences                     China             Prof. De-an Guo
  Tongji University                                                                     China             Prof. Gang Pei
  Tasly Institute of Tasly Group Co., Ltd.                                              China             Ms. Karolina J. Svedlund
  Tianjin University of Traditional Chinese Medicine                                    China             Prof. Boli Zhang
  University of Macau                                                                   China             Prof. Yi-Tao Wang
  The Chinese University of Hong Kong                                                   China             Prof. Ge Lin
  Pfizer Corporation Hong Kong Ltd                                                      China             Mr. Stephen Leung
  State Food and Drug Administration                                                    China             Prof. Zhong-zhi Qian
  National Research Institute of Chinese Medicine, Taiwan                               China             Prof. Yi-Tsau Huang
  University of Aarhus                                                                  Denmark           Prof. Brian Clark
  University of Oulu                                                                    Finland           Prof. Olavi Pelkonen
  Public Research Centre of Health                                                      Luxembourg        Dr. Ning Wang
  Charité University Medical Center                                                     Germany           Prof. Claudia M. Witt
  Johannes Gutenberg University                                                         Germany           Dr. Huige Li
  University of Regensburg                                                              Germany           Prof. Gerhard Franz
  Philipps - Universität Marburg                                                        Germany           Prof. Shuming Li
  Max Planck Institute for Biophysics                                                   Germany           Prof. Wolfgang Schwarz
  Dr Willmar Schwabe GmbH & Co. KG                                                      Germany           Dr. Günter Meng
  Caesar & Loretz GmbH                                                                  Germany           Dr. Mirko Bayer
  University of Cagliari                                                                Italy             Prof. Enzo Tramontano
  University of Rome Tor Vergata                                                        Italy             Prof. Giovanna M. Franconi
  Institute of Neurobiology and Molecular Medicine, Italian National Research Council   Italy             Dr. Luigi Manni
  SU BioMedicine                                                                        The Netherlands   Prof. Jan van der Greef
  Norwegian University of Science and Technology                                        Norway            Prof. Odd Georg Nilsen
  Thailand Ministry of Public Health                                                    Thailand          Dr. Prat Boonyawongviroj
  School of Pharmacy                                                                    UK                Prof. Michael Heinrich
  Brunel University                                                                     UK                Prof. Ian A. Sutherland
  University of Reading                                                                 UK                Prof. Elizabeth Williamson
  Guy\'s & St Thomas\' NHS Foundation Trust                                             UK                Prof. Debbie Shaw
  University of Nottingham                                                              UK                Prof. Sue Watson
  University of Warwick                                                                 UK                Prof. Kenneth Muir
  University of Westminster                                                             UK                Dr. Volker Scheid
  University of Lincoln                                                                 UK                Dr. Huijun Shen
  Thames Valley University                                                              UK                Prof. Nicola Robinson
  University of the West England                                                        UK                Prof. Quan Min Zhu
  Imperial College London                                                               UK                Dr. Daqing Ma
  Global Regulatory Services                                                            UK                Mrs. Greer Deal
  Link China Pharma Solutions                                                           UK                Mr. Marshall Ma
  University of Oxford                                                                  UK                Ms. Rebecca Richmond
  University of East London                                                             UK                Dr. Tianjun Wang
  Pharsafer Associates Limited                                                          UK                Dr. Graeme Ladds
  Avicenna                                                                              UK                Mr. Mazin Al-Khafaji
  University of Louisville                                                              USA               Prof. Y. James Kang
  Yale University                                                                       USA               Prof. Yung-Chi Cheng
  U.S. Food and Drug Administration                                                     USA               Dr. Shaw T. Chen
  Vanderbilt University Medical Center                                                  USA               Dr. Lijun Ma
  Independent                                                                           UK                Dr. Shouming Zhong
  Independent                                                                           UK                Dr. Daryl Rees

Progress and difficulties
-------------------------

During the first 18 months of the project (May 2009-October 2010), the management team (WP10) has coordinated a highly successful team build-up and re-construction. With the ever-strengthening expertise pool, WP10 has developed a number of committees and panels that lead the consortium with clear divisions of labour. WP10 has led the design and updates of the professional GP-TCM website and all WPs have established their homepages and online discussion facilities. Periodic newsletters have enabled members to share information and stay as a united team. Significantly, a series of face-to-face meetings, including consortium and WP kick-off meetings and the 1^st^Annual General Meeting, have been organised to monitor the consortium, promote interactions and collaborations and ensure milestones are met and deliverables accomplished on time and in high quality.

Noteworthy WP-specific achievements are as follows. WP1 led the creation of a list of nearly 300 species of plants and fungi commonly used in TCM in Europe and China and a priority list of 11 species will be used by all WPs in their initial literature analysis. WP2 worked jointly with WP1, linking quality control, extraction technology and chemical analysis, with special emphasis on the important role of *paozhi*(processing) in the production of CHM. WP3 produced a list of toxic plants for further literature study and identified 3 major fields of action: (i) investigation of methods (classical and functional genomics) applicable to toxicity evaluation; (ii) study of toxicological reports available on a series of CHM; (iii) review of pharmacovigilance safety data. WP4 established evaluation criteria for scoring scientific articles and began the creation of an appropriate database of literature encompassing functional genomic applications in CHM research. WP5 performed reviews on CHM literature involving animal models, especially models of cancer and its conclusions have laid a solid foundation for further literature analysis on application of functional genomics in CHM research and proposing good practice in animal studies of CHM. WP6 gathered literature on seminal studies in clinical CHM studies and drafted a guideline on clinical trials of CHM. WP6 and WP8 collaboratively designed an online survey targeting TCM practitioners and the survey is currently undergoing in collaboration with 30 professional acupuncture and TCM organisations. WP7 brought together wide-ranging experiences and expertise in drug development and registration from Europe, China, Australia and North America to discuss the legislative and regulatory issues relevant to CHM. Together they are developing a comprehensive document providing comparisons of different practices on CHM regulations and this will be extremely helpful for the EU to develop its future policies and for companies to develop products for the global market. WP9 discussed the time and format of the Final Conference and preliminary bookings of venue has been made.

The major difficulty encountered by the consortium is unsurprisingly the language barrier. There is a lack of accessibility to original Chinese publications in Europe, and even if they are available, fast and accurate translation of these materials is impossible, preventing the consortium from extensively studying classic Chinese medical literature and evaluating a great deal of modern Chinese medical literature. While we strongly encourage our members to master both English and Chinese languages, we welcome members from various linguistic, ethnic and cultural backgrounds to work in close collaboration.

Further work
------------

As the first ever EU-China collaborative consortium dedicated to TCM research, we will continue to promote EU-China dialogues and collaborations in this important emerging supra-disciplinary area. As a network of principal investigators, we will collaborate to train the next generation of scientists who are more comprehensively equipped to study complex drugs such as CHM and personalised medicine such as TCM. As a coordination action involving much literature review and evaluation, we acknowledge the huge importance of good practice in scientific publication and will continue to support open-access publications.

Concluding remarks
------------------

As an EU-China collaboration dedicated to TCM research, we are keen to incorporate ourselves into the worldwide landscape of TCM research community and serve as a constructive member. We sincerely support the international TCM community to bundle forces to improve TCM research funding from both the public and private sectors and to help shape the medicine of tomorrow together.
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